Top

Breast Cancer Research and Treatment

Published in:

01-12-2009 | Letter to the editor

Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2

Authors: Ke-Da Yu, Gen-Hong Di, Lei Fan, Zhen Hu, Ao-Xiang Chen, Zhi-Ming Shao

Published in: Breast Cancer Research and Treatment | Issue 3/2009

Excerpt

To the Editor, …

Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358:2796–2803. doi:10.1056/NEJMsa0708739 CrossRefPubMed

Subramanian A, Salhab M, Mokbel K (2008) Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res Treat 111:191–202. doi:10.1007/s10549-007-9788-0 CrossRefPubMed

Gonzalez-Zuloeta Ladd AM, Vasquez AA, Rivadeneira F, Siemes C, Hofman A, Stricker BH, Pols HA, Uitterlinden AG, van Duijn CM (2008) Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 107:415–419. doi:10.1007/s10549-007-9562-3 CrossRefPubMed

Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108:137–149. doi:10.1007/s10549-007-9586-8 CrossRefPubMed

Talbott KE, Gammon MD, Kibriya MG, Chen Y, Teitelbaum SL, Long CM, Gurvich I, Santella RM, Ahsan H (2008) A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk. Breast Cancer Res Treat 111:481–487. doi:10.1007/s10549-007-9794-2 CrossRefPubMed

Yu K-D, Di G-H, Yuan W-T, Fan L, Wu J, Hu Z, Shen Z-Z, Zheng Y, Huang W, Shao Z-M (2009) Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum Mol Genet. doi:10.1093/hmg/ddp171

Wang W, Le WD, Pan T, Stringer JL, Jaiswal AK (2008) Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson’s disease. J Gerontol A Biol Sci Med Sci 63:127–134PubMed

Harada S, Fujii C, Hayashi A, Ohkoshi N (2001) An association between idiopathic Parkinson’s disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 288:887–892. doi:10.1006/bbrc.2001.5868 CrossRefPubMed

Title: Caution regarding genotyping methodology for a tri-allelic polymorphism in the novel breast cancer susceptibility gene NQO2
Authors: Ke-Da Yu
Gen-Hong Di
Lei Fan
Zhen Hu
Ao-Xiang Chen
Zhi-Ming Shao
Publication date: 01-12-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0431-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2009

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients

STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects

Genomic analysis from tissue core biopsies: standard of care for the future?

Opposite effects of protein kinase C beta1 (PKCβ1) and PKCε in the metastatic potential of a breast cancer murine model

Meta-analysis of gene expression profiles related to relapse-free survival in 1,079 breast cancer patients

‘Minority report’: how best to analyze clinical trial data to address disparities

Keynote webinar | Spotlight on antibody–drug conjugates in cancer